LON:SALV SalvaRx Group (SALV) Share Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free SALV Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 4.50▼ 4.5052-Week Range N/AVolume50,758 shsAverage Volume50,758 shsMarket Capitalization£1.65 millionP/E Ratio0.03Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get SalvaRx Group alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About SalvaRx GroupSalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story SALV Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive SALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SalvaRx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SALV Previous SymbolLON:3LEG CUSIPN/A CIKN/A Webwww.salvarx.io Phone+44-1624-811611FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.03 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio14.50 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales£64.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.50 Book ValueGBX 15.40 per share Price / BookN/AMiscellaneous Outstanding Shares36,700,000Free FloatN/AMarket Cap£1.65 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Denham Hervey Newall Eke (Age 67)CFO & Director Key CompetitorsPhysiomicsLON:PYCNuformixLON:NFXReNeuron GroupLON:RENEEvgen PharmaLON:EVGPort Erin Biopharma InvestmentsLON:PEBIView All Competitors SALV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of SalvaRx Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other SalvaRx Group investors own include Premier African Minerals (PREM), Cradle Arc (CRA), Cora Gold (CORA), Big Sofa Technologies Group (BST), Bahamas Petroleum (BPC), Bacanora Lithium (BCN), AutoZone (AZO), Angus Energy (ANGS), Allergy Therapeutics (AGY) and AFR.L (AFR). How do I buy shares of SalvaRx Group? Shares of SALV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SALV) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SalvaRx Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.